Tr1x Stock

www.tr1x.bioHealthcare / BioTech & PharmaFounded: 2018

Tr1x is a biotechnology company striving to find new cellular immunotherapies for people living with autoimmune and inflammatory conditions. The team is aiming to find a remedy for autoimmune and inflammatory diseases through their research that applies the therapies. Tr1x was founded in 2018 by Maria Grazia Roncarolo, M.D., the person who discovered Type 1 regulatory T (Tr1) cells, and is headquartered in La Jolla, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Tr1x, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Tr1x’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Tr1x.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Tr1x investors also invested in these private companies


Management Team

Maria Roncarolo Ph.D
Co-Founder, President & Head of Research and Development
David de Vries
Co-Founder & Chief Operating Officer
Jan deVries Ph.D
Jonathan Perrin JD
Co-Founder, Senior Director of Operations & General Counsel
William Lis
Chief Executive Officer
James Adams
Chief Technology Officer
Xavier Paliard Ph.D
Chief Scientific Officer

Board Members

Leon Chen Ph.D
The Column Group

Frequently Asked Questions About Tr1x’s Stock

Can you buy Tr1x’s stock?
Tr1x is not publicly traded on NYSE or NASDAQ in the U.S. To buy Tr1x’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Tr1x’s stock?
Yes, you can sell stock of a private company like Tr1x. Forge can help you sell your Tr1x stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Tr1x’s stock price?
Tr1x is a privately held company and therefore does not have a public stock price. However, you may access Tr1x’s private market stock price with Forge Data.
What is Tr1x’s stock ticker symbol?
Tr1x does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Cell Therapy Startup Tr1X Emerges from Stealth with $75M Series A
Tr1X came out of stealth mode on Wednesday with $75 million in Series A funding as it looks to bring allogeneic engineered Treg and CAR-Treg cell therapies to treat major autoimmune diseases into the clinic this year. The funding round was led by The Column Group and had participation from Alexandria Ventures and NEVA SGR.
Updated on: Jun 14, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.